Citations

Showing 10 of 108104 citations.

Epidemiology of infective endocarditis: novel aspects in the twenty-first century
Arshad, Verda , Talha, Khawaja M. , Baddour, Larry M. , Baddour, Larry

Mayo Clinic

Expert Review of Cardiovascular Therapy | January 27, 2022 | Volume: 20 | Issue: 1 | Pages: 45-54

10.1080/14779072.2022.2031980 | PMID 35081845 Get It

Association of annual volume and in‐hospital outcomes of catheter‐directed thrombolysis for pulmonary embolism
Jung, Richard G. , Simard, Trevor , Hibbert, Benjamin , Harris, Alyssa Hartsell, Hohmann, Samuel F. , Giri, Jay , Bashir, Riyaz , Hibbert, Benjamin , Simard, Trevor , Harris, Alyssa , Alkhouli, Mohamad

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 27, 2022 | Volume: 99 | Issue: 2 | Pages: 440-446

10.1002/ccd.30080 | PMID 35083846 Get It

Abstract Objective We sought to evaluate the association between the institutional volume of catheter‐directed thrombolysis (CDT) for pulmonary embolism and in‐hospital mortality. Background CDT is an increasingly utilized therapy in patients with intermediate/high‐risk PE. However, data on the relationship between hospital volume and clinical outcomes remain limited. Methods Patients who underwent CDT between October 1, 2015, and March 31, 2021, were identified in the Vizient Clinical Database. The primary outcome was in‐hospital mortality. Secondary outcome were major complications, length of stay, and cost. Hospitals were dichotomized into <8 and 8 cases/year following restricted cubic spline analysis. Results A total of 6741 CDT procedures at 171 hospitals were included with a median annual hospital volume of 4.1 cases (IQR = 1.9–8.3). A total of 44 hospitals (25.7%) were classified as high‐volume (8 cases/year) and performed 60.9% of all CDT cases. CDT at high‐volume centers was associated with lower in‐hospital mortality (6.0% vs. 11.3%; p < 0.0001). Stroke and bleeding rates were similar, but pulmonary complications were more frequent at low‐volume centers. CDT at high volume centers was associated with a significantly shorter length of stay and lower cost. The association between high CDT volume and in‐hospital mortality persisted after adjustment for demographics (odds ratio [OR] = 0.49, [0.41–0.58]), demographics and risk factors (OR = 0.52 [0.44–0.62]), and demographics, risk factors, and troponin elevation (OR = 0.51 [0.40–0.66]). Conclusion In a large contemporary cohort of patients undergoing CDT in the United States, low annual institutional volume of CDT was associated with higher in‐hospital mortality.
Florida House Bill 451 was not Associated with a Decrease in Postoperative Opioid Prescribing for Acute Pain at a Single Institution
Glasgow, Amy E. , Habermann, Elizabeth B. , Glasgow, Amy E. , Porter, Steven B , Habermann, Elizabeth , Glasgow, Amy E , Porter, Steven B.

Mayo Clinic

The American Surgeon | January 26, 2022 | Volume: 88 | Issue: 7 | Pages: 1708-1709

10.1177/00031348221074237 | PMID 35081794 Get It

Intracranial neuroendocrine tumour simulating meningioma for several years: an overview of diagnosis and treatment
Badawy, Mohamed , Johnson, Geoffrey B. , Jain, Manoj , Porter, Alyx B. , Yang, Ming , Kendi, Ayse Tuba, Porter, Alyx, Sonbol, Mohamad Bassam , Johnson, Geoffrey B , Kendi, A. Tuba , Johnson, Derek R.

Mayo Clinic

BJR|case reports | January 26, 2022 | Volume: 8 | Issue: 3 | Pages: No page available

10.1259/bjrcr.20210222 | PMID 36101727 Get It

Metastatic neuroendocrine tumour (NET) to brain has been reported in 1.5–5% of patients with NETs. Differentiation between intracranial NET metastasis and meningiomas can cause a diagnostic dilemma. We present a symptomatic case of a 66-year-old male with a history of left-sided skull base mass. The diagnosis of a meningioma was made based on the MRI findings and clinical presentation. The patient received radiation and the mass remained stable on serial MRI images at follow-up visits. Five years after his initial presentation, the patient’s mass showed further growth. He also complained of worsening of his recent diagnosis of irritable bowel syndrome and fluctuations in his blood pressure. Surgical resection was performed, and histopathological features were consistent with moderately differentiated neuroendocrine tumour. Further evaluation with 68 Gallium-DOTATATE positron emission-computed tomography (Ga-68 PET/CT) showed metastatic disease involving the bones, lymph nodes, and liver without convincing evidence of the location of primary malignancy within the bowel loops or the pancreas. The patient was started on combination of capecitabine and temozolomide with partial response and significant improvement of his symptoms. This case highlights the clinical and radiological behaviour of intracranial NET that can mimic the diagnosis of meningioma.
Vancomycin Should Be Considered a Nephrotoxic Antimicrobial Agent: PRO
Murphy, Mark , Frazee, Erin N. , Murphy, Mark E , Frazee, Erin N

Mayo Clinic

Kidney360 | January 26, 2022 | Volume: 3 | Issue: 9 | Pages: 1484-1487

10.34067/kid.0008032021 | PMID 36245668 Get It

Readmissions From Venous Thromboembolism After Complex Cancer Surgery
Mallick, Saad, Aiken, Taylor , Varley, Patrick R., Abbott, Daniel E. , Tzeng, Ching‐Wei, Weber, Sharon M. , Wasif, Nabil , Zafar, Syed Nabeel

Mayo Clinic

JAMA Surgery | January 26, 2022 | Volume: 157 | Issue: 4 | Pages: 312

10.1001/jamasurg.2021.7126 | PMID 35080619 Get It

Cost-effectiveness and Economic Benefit of Continuous Professional Development for Drug Prescribing
Cook, David A. , Stephenson, Christopher R. , Wilkinson, John M. , Foo, Jonathan , Foo, J , Maloney, Stephen

Mayo Clinic

JAMA Network Open | January 26, 2022 | Volume: 5 | Issue: 1 | Pages: e2144973

10.1001/jamanetworkopen.2021.44973 | PMID 35080604 Get It

Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer
Broeck, Thomas Van den, Moris, Lisa, Gevaert, Thomas, Davicioni, Elai , Boeckx, Bram, Lambrechts, Diether , Helsen, Christine , Handle, Florian , Ghesquière, Bart , Soenen, Stefaan, Smeets, Elien, Eerlings, Roy , Kharraz, Sarah El , Devlies, Wout, Karnes, R. Jeffrey, Lotan, Tamara, Poppel, Hendrik Van, Joniau, Steven , Claessens, Frank , Lambrechts, Diether , El Kharraz, Sarah , Lambrechts, Diether , Davicioni, Elai , Lambrechts, Diether , Joniau, Steven , Ghesquière, Bart , Broeck, Thomas Van den, Moris, Lisa, Gevaert, Thomas, Boeckx, Bram, Helsen, Christine , Handle, Florian , Soenen, Stefaan, Smeets, Elien, Eerlings, Roy , Devlies, Wout , Karnes, R. Jeffrey, Lotan, Tamara, Poppel, Hendrik Van, Claessens, Frank

Mayo Clinic

Molecular Cancer Research | January 26, 2022 | Volume: 20 | Issue: 4 | Pages: 527-541

10.1158/1541-7786.mcr-21-0388 | PMID 35082164 Get It

Abstract Molecular drivers of metastasis in patients with high-risk localized prostate cancer are poorly understood. Therefore, we aim to study molecular drivers of metastatic progression in patients with high-risk prostate cancer. A retrospective matched case-control study of two clinico-pathologically identical groups of patients with high-risk prostate cancer was undertaken. One group developed metastatic recurrence (n = 19) while the other did not (n = 25). The primary index tumor was identified by a uro-pathologist, followed by DNA and RNA extraction for somatic copy-number aberration (SCNA) analysis and whole-transcriptome gene expression analysis. In vitro and in vivo studies included cell line manipulation and xenograft models. The integrative CNA and gene expression analyses identified an increase in Antizyme Inhibitor 1 (AZIN1) gene expression within a focal amplification of 8q22.3, which was associated with metastatic recurrence of patients with high-risk prostate cancer in four independent cohorts. The effects of AZIN1 knockdown were evaluated, due to its therapeutic potential. AZIN1 knockdown effected proliferation and metastatic potential of prostate cancer cells and xenograft models. RNA sequencing after AZIN1 knockdown in prostate cancer cells revealed upregulation of genes coding for collagen subunits. The observed effect on cell migration after AZIN1 knockdown was mimicked when exposing prostate cancer cells to bio-active molecules deriving from COL4A1 and COL4A2. Our integrated CNA and gene expression analysis of primary high-risk prostate cancer identified the AZIN1 gene as a novel driver of metastatic progression, by altering collagen subunit expression. Future research should further investigate its therapeutic potential in preventing metastatic recurrence. Implications: AZIN1 was identified as driver of metastatic progression in high-risk prostate cancer through matrikine regulation.
Timely Turnaround: A Humble Request to Employers
Kandi, Lyndsay A., Howard, Michael A., Casey, William J., Song, David H., Teven, Chad M., Kandi, Lyndsay A. , Howard, Michael A., Casey, William J., Song, David H., Teven, Chad M.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 26, 2022 | Volume: 10 | Issue: 1 | Pages: e4070

10.1097/gox.0000000000004070 | PMID 35186627 Get It